Table 2 –
Baseline clinical and pathologic characteristics, by Wnt status
| Wnt mutation (N = 15) | No Wnt mutation (N = 122) | |
|---|---|---|
| Age at diagnosis, median (Q1, Q3) | 60 (58–66) | 62 (56–68) |
| Age at ADT starting, median (Q1, Q3) | 64 (59–66) | 65 (58–69) |
| Race, N (%) | ||
| White | 13 (87) | 98 (81) |
| Black | 2 (13) | 17 (14) |
| Other | 0 (0) | 6 (5) |
| Baseline PSA (ng/ml) prior to starting abiraterone or enzalutamide, median (Q1, Q3) | 21.8 (6.3–75.8) | 14.5 (5.6–46.2) |
| Time from diagnosis to first-line abi/enza, mo (Q1, Q3) | 56.3 (22.6–79.7) | 41.9 (19.4–83.4) |
| Time to castration-resistance, mo (Q1, Q3) | 14.6 (8.3–33.4) | 17.3 (11.9–28.5) |
| Gleason grade group, N (%) | ||
| Grade 1 | 0 (0) | 2 (1.7) |
| Grade 2 | 1 (6.7) | 11 (9.6) |
| Grade 3 | 3 (20) | 13 (11) |
| Grade 4 | 2 (13) | 20 (17) |
| Grade 5 | 9 (60) | 69 (60) |
| Radical prostatectomy, N (%) | 9 (60) | 46 (38) |
| Pathologic/clinical T stage, N (%) | ||
| T1/T2 | 9 (69) | 52 (49) |
| T3/T4 | 4 (31) | 55 (51) |
| Pathologic pN+, N (%) | 3 (33) | 8 (18) |
| Metastasis at diagnosis, N (%) | 4 (27) | 50 (42) |
| Ductal or intraductal histology, N (%) | 3 (20) | 15 (14) |
| Perineural invasion, N (%) | 8 (57) | 63 (61) |
| Lymph vascular invasion, N (%) | 1 (7.1) | 13 (13) |
| Previous taxane chemotherapy, N (%) | 11 (73) | 62 (51) |
| Taxane chemotherapy for mHSPC, N (%) | 2 (13) | 16 (13) |
| Concurrent p53 mutation, N (%) | 5 (33) | 49 (40) |
| Sites of metastatic disease, N (%) | ||
| Bone | 12 (80) | 109 (89) |
| Lymph node | 9 (60) | 83 (68) |
| Visceral | 7 (47) | 38 (31) |
| Source of somatic DNA, N (%) a | ||
| Prostate | 5 (33) | 65 (53) |
| Metastasis | 8 (53) | 44 (36) |
| Plasma tumor DNA | 3 (20) | 21 (17) |
abi = abiraterone; ADT = androgen deprivation therapy; enza = enzalutamide; mHSPC = metastatic hormone-sensitive prostate cancer; PSA = prostate-specific antigen.
a
The sum of percentages exceeds 100% because some patients had more than one test.